CV Sciences (San Diego, CA) has introduced a new product to its Wellness line of CBD products called +PlusCBD Relief Softgels. According to CV Sciences, the product delivers seven times more CBDA and CBD than the original +PlusCBD raw formula, and also features Levagen+ PEA (palmitoylethanolamide), which has the ability to influence the endocannabinoid system, and has been shown in research to be similarly effective to NSAIDs, such as ibuprofen. For example, one triple-blind randomized clinical trial found that subjects suffering from temporomandibular joint (TMJ) osteoarthritis or arthralgia found that subjects taking 300 mg of PEA in the morning and 600 mg in evening, then 300 mg of PEA twice daily for seven days experienced a significantly higher decrease in pain than subjects taking 600 mg of ibuprofen three times per day for two weeks.1 The optimized combination is therefore designed to promote healthy inflammatory response and help to safely manage soreness.
“We believe that +PlusCBD Relief Softgels contain the safest, purest and most effective source of CBD/CBDA available on the market today,” said Joseph Dowling, chief executive officer of CV Sciences, in a press release. “Our work at CV Sciences centers around the potential for CBD to transform our understanding of health, wellness and pain relief. The +PlusCBD Relief Softgels represent another step in our mission to offer innovative and safe alternatives to improve health, leveraging CBD/CBDA and PEA. Our product development team creates best-in-class, innovative products that suit individual preferences, address need states and help consumers benefit from CBD in the way that works best for them.”
Reference
- Marini I et al. “Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain.” Journal of Orofacial Pain, vol. 26, no. 2 (2012); 99-104
